The New Frontier of Biotherapeutics: Advancing Bispecific Antibody Engineering and Assessment
The landscape of immunotherapy has undergone a seismic shift over the last decade. While monoclonal antibodies (mAbs) laid the foundation for targeted treatment, the emergence of bispecific antibodies (BsAbs) has opened doors to therapeutic possibilities that were once deemed unreachable. By simultaneously binding to two different antigens or epitopes, BsAbs can bridge T-cells to tumor...
0 Komentáře 0 Sdílení 127 Shlédnutí 0 Hodnocení